Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 19
2003 11
2004 16
2005 19
2006 19
2007 35
2008 20
2009 14
2010 14
2011 28
2012 29
2013 18
2014 21
2015 22
2016 22
2017 24
2018 26
2019 38
2020 30
2021 40
2022 24
2023 16
2024 13
2025 8
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

472 results

Results by year

Filters applied: . Clear all
Page 1
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment.
Hirabae A, Kuribayashi T, Tomida S, Okawa S, Nakasuka T, Nishii K, Nishimura J, Makimoto G, Ninomiya K, Higo H, Rai K, Ichihara E, Hotta K, Sugimoto M, Togashi Y, Maeda Y, Kiura K, Ohashi K. Hirabae A, et al. Among authors: kiura k. Curr Oncol. 2026 May 27;33(6):315. doi: 10.3390/curroncol33060315. Curr Oncol. 2026. PMID: 42346215 Free PMC article.
Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model.
Tanaka T, Fujitani M, Taoka M, Shimomura I, Okawa S, Mori S, Kuribayashi T, Nishimura J, Nishimura T, Morita A, Hara N, Ninomiya K, Makimoto G, Higo H, Rai K, Ichihara E, Tomida S, Hotta K, Togashi Y, Maeda Y, Kiura K, Katayama R, Ohashi K. Tanaka T, et al. Among authors: kiura k. Cancer Sci. 2026 Jun 1:10.1111/cas.70431. doi: 10.1111/cas.70431. Online ahead of print. Cancer Sci. 2026. PMID: 42226508 Free PMC article.
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancer.
Nishimura J, Kuribayashi T, Brägelmann J, Okawa S, Taoka M, Mori S, Nishimura T, Tanaka T, Makimoto G, Ninomiya K, Rai K, Ichihara E, Katayama R, Hotta K, Tabata M, Togashi Y, Maeda Y, Sos ML, Kiura K, Ohashi K. Nishimura J, et al. Among authors: kiura k. Mol Oncol. 2026 May 21:10.1002/1878-0261.70264. doi: 10.1002/1878-0261.70264. Online ahead of print. Mol Oncol. 2026. PMID: 42169500 Free PMC article.
TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.
Kuribayashi T, Nishimura J, Okawa S, Taoka M, Mori S, Tanaka T, Nishimura T, Morita A, Hara N, Ninomiya K, Makimoto G, Rai K, Ichihara E, Hotta K, Togashi Y, Maeda Y, Kiura K, Ohashi K. Kuribayashi T, et al. Among authors: kiura k. Cancer Sci. 2026 May;117(5):1260-1272. doi: 10.1111/cas.70352. Epub 2026 Feb 27. Cancer Sci. 2026. PMID: 41757675 Free PMC article.
Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study.
Tsubata Y, Kanaji N, Nakao M, Masuda T, Yamasaki M, Kodani M, Ishikawa N, Kozuki T, Inoue M, Nishii K, Hotta K, Kiura K, Isobe T. Tsubata Y, et al. Among authors: kiura k. Respir Investig. 2026 Jan;64(1):101332. doi: 10.1016/j.resinv.2025.11.011. Epub 2025 Nov 22. Respir Investig. 2026. PMID: 41275531 Free article.
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study.
Saeki S, Hotta K, Sakata S, Oda N, Inoue K, Tamura T, Toyozawa R, Harada D, Tanaka K, Inoue K, Shioyama Y, Gemba K, Sasaki T, Bessho A, Kishimoto J, Katsui K, Kiura K, Sugio K. Saeki S, et al. Among authors: kiura k. Cureus. 2025 Jun 23;17(6):e86575. doi: 10.7759/cureus.86575. eCollection 2025 Jun. Cureus. 2025. PMID: 40704256 Free PMC article.
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation.
Okawa S, Tomida S, Kuribayashi T, Nishimura J, Nakasuka T, Hirabae A, Hara N, Inoue H, Makimoto G, Ninomiya K, Rai K, Ichihara E, Hotta K, Tabata M, Maeda Y, Kiura K, Ohashi K. Okawa S, et al. Among authors: kiura k. Mol Cancer Ther. 2025 Nov 3;24(11):1763-1774. doi: 10.1158/1535-7163.MCT-25-0002. Mol Cancer Ther. 2025. PMID: 40439218
472 results